sunitinib teva 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
advantan 1 mg/g krema
bayer d.o.o. - metilprednizolonaceponat - krema - metilprednizolonaceponat 1 mg / 1 g - metilprednizolonaceponat
advantan 1 mg/g krema
bayer d.o.o. - metilprednizolonaceponat - krema - metilprednizolonaceponat 1 mg / 1 g - metilprednizolonaceponat
advantan 1 mg/g mazilo
bayer d.o.o. - metilprednizolonaceponat - mazilo - metilprednizolonaceponat 1 mg / 1 g - metilprednizolonaceponat
advantan 1 mg/g mazilo
bayer d.o.o. - metilprednizolonaceponat - mazilo - metilprednizolonaceponat 1 mg / 1 g - metilprednizolonaceponat
veregen 100 mg/g mazilo
nordic pharma, s.r.o. - suhi ekstrakt lista čajevca, prečiščeni - mazilo - suhi ekstrakt lista čajevca, prečiščeni 100 mg / 1 g - sinekatehini
veregen 100 mg/g mazilo
nordic pharma, s.r.o. - suhi ekstrakt lista čajevca, prečiščeni - mazilo - suhi ekstrakt lista čajevca, prečiščeni 100 mg / 1 g - sinekatehini
vidaza
bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
softiflox- dcp
synulox r.t.u
zoetis belgium rue laid burniat 1 1348 louvain -